S-1: Microbot Medical Files for Potential Resale of 1.77 Million Common Shares Issuable Upon Exercise of Preferred Investment Options

Microbot Medical has filed a registration statement for the potential resale of up to 1,769,966 shares of its common stock, issuable upon the exercise of outstanding preferred investment options held by selling stockholders.

Summary

• Microbot Medical has filed a Form S-1 registration statement with the SEC relating to the potential sale or disposition of up to 1,769,966 shares of its common stock.
• These shares are issuable upon the exercise of outstanding preferred investment options held by selling stockholders.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• Microbot Medical is a pre-clinical medical device company focused on developing robotic endoluminal surgery devices.
• Their primary focus is on the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures.
• The company's cash resources are sufficient to fund operations through approximately June 2024.
• Microbot is seeking additional capital to continue the development of the LIBERTY system.
• The company is involved in ongoing litigation with Empery and Hudson Bay, seeking rescission of a Securities Purchase Agreement and return of $6.75 million.
• Microbot plans to submit an Investigational Device Exemption (IDE) application to the FDA in the first quarter of 2024 to commence a pivotal clinical trial in humans for the LIBERTY system.
• The company is also pursuing CE Mark approval to market the LIBERTY system in Europe.
• Microbot has ceased research and development activities not related to the LIBERTY Endovascular Robotic Surgical System.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments regarding the LIBERTY system and regulatory progress, the financial risks, litigation, and going concern uncertainty weigh heavily on the overall outlook.

Positives

• Successful completion of pre-clinical studies for the LIBERTY Endovascular Robotic Surgical System, with a 95% success rate in reaching vascular targets.
• Plans to submit an IDE application to the FDA in Q1 2024 to commence human clinical trials for the LIBERTY system.
• Pursuing CE Mark approval to market the LIBERTY system in Europe.
• Appointment of Dr. Juan Diaz-Cartelle as Chief Medical Officer to lead clinical strategy and regulatory process.
• Strategic collaboration agreement with Stryker Corporation for technology co-development.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company has incurred significant operating losses since inception and expects to continue to do so.
• Microbot is subject to ongoing litigation, which could have a material adverse effect on its financial condition.
• The company's future success depends heavily on the commercialization of the LIBERTY Endovascular Robotic Surgical System.
• Delays in the supply of certain components from Israeli-based vendors due to the Israel-Hamas war could affect the IDE submission timeline.

Risks

• The company's ability to continue as a going concern is uncertain due to limited cash resources and ongoing operating losses.
• The outcome of the litigation with Empery and Hudson Bay could significantly impact the company's financial position.
• Delays in obtaining regulatory clearances or approvals for the LIBERTY system could harm the company's business.
• The company's operations in Israel are subject to political, economic, and military risks.
• The company's reliance on third-party manufacturers and suppliers poses risks to its supply chain and production capabilities.
• The company's intellectual property rights may not be adequately protected, and it could face infringement claims.
• The company may not be able to obtain adequate levels of third-party reimbursement for procedures involving its product candidates.

Future Outlook

The company plans to submit an IDE application to the FDA in the first quarter of 2024 and is seeking additional capital to fund operations beyond June 2024. The company is also pursuing CE Mark approval for the LIBERTY system in Europe.

Industry Context

Microbot Medical operates in the competitive medical device industry, specifically targeting the minimally invasive surgery space. The company faces competition from established players with greater financial resources and expertise. The success of the LIBERTY system depends on its acceptance by the medical community and its ability to compete with existing and emerging technologies.

Comparison to Industry Standards

• Companies like Intuitive Surgical (ISRG) and Stryker (SYK) are major players in the surgical robotics market, but Microbot is focusing on a fully disposable system, which is a differentiator.
• Medtronic (MDT) and Johnson & Johnson (JNJ) also have significant presence in the endovascular space, but Microbot's LIBERTY system aims to offer unique advantages in terms of size, disposability, and remote control capabilities.
• Globally, companies like Siemens Healthineers (SHL) are also investing in robotic surgery and imaging technologies, creating a competitive landscape for Microbot.
• The success of Microbot's LIBERTY system will depend on its ability to demonstrate superior clinical outcomes, cost-effectiveness, and ease of use compared to existing technologies and competing products.

Management Changes

Legal Proceedings

• The company is the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., Plaintiffs, against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020).
• The complaint alleges, among other things, that the company breached multiple representations and warranties contained in the Securities Purchase Agreement (the SPA) related to its June 8, 2017 equity financing (the Financing).
• The complaint seeks rescission of the SPA and return of the Plaintiffs $6.75 million purchase price with respect to the Financing.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of shares upon exercise of outstanding warrants and options.
• Employees may be affected by cost reduction plans and potential changes in compensation and benefits.
• Customers (healthcare providers and patients) could benefit from the development and commercialization of the LIBERTY system, but its success is not guaranteed.
• Suppliers and vendors may be impacted by the company's financial situation and potential changes in its operations.
• Creditors face increased risk due to the company's uncertain financial position and ability to continue as a going concern.

Next Steps

• Submit the Investigational Device Exemption (IDE) application to the FDA in the first quarter of 2024.
• Commence pivotal clinical trial in humans, pending FDA approval.
• Commence audits for ISO 13485 certification to ensure compliance with EU Medical Devices Regulation (MDR 2017/745) during the first half of 2024.
• Continue seeking new sources of capital to stabilize finances and provide operating runway subsequent to June 2024.

Key Dates

Keywords

LIBERTY Endovascular Robotic Surgical System, preferred investment options, common stock, FDA, clinical trials, CE Mark, Microbot Medical, IDE, robotics, medical device